Peritoneal Cancer
📧 Sign up to get email alerts when something new happens for Peritoneal Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]
This Phase 3 trial evaluated bevacizumab in addition to standard therapy for newly diagnosed Stage III/IV epithelial ovarian, fallopian tube…
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating pembrolizumab after weekly paclitaxel in platinum-resistant ovarian, fallopian tube, or peritoneal cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating irinotecan liposome with bevacizumab for platinum-resistant or recurrent ovarian, fallopian tube, or prima…
-
CLINICAL_TRIALS trial_result · 2022-12-29Clinical Trial Update: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma [Phase 2]
Phase 2 clinical trial evaluating bevacizumab with modified FOLFIRINOX for mucinous ovarian, fallopian tube, or primary peritoneal cancers.
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer [Phase 3]
A single-arm Phase 3 trial of IMGN853 in Chinese adults with platinum-resistant epithelial ovarian cancer is ongoing, with conditions includ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-11-14FDA Approved: ELAHERE — Original Application (ImmunoGen, Inc.)
The FDA approved ELAHERE (mirvetuximab soravtansine) from ImmunoGen as the original approval for FRα-positive, platinum-resistant epithelial…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial evaluating gemcitabine hydrochloride alone or in combination with M6620 for recurrent ovarian, fallopian tube, or pri…
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation [Phase 2]
Phase 2 trial evaluating the combination of olaparib, durvalumab, and tremelimumab in patients with BRCA1/BRCA2-mutated recurrent or refract…
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab [NA]
Clinical trial assessing perfusion CT to predict outcomes in ovarian, fallopian tube, or peritoneal cancer treated with bevacizumab; the stu…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [Phase 2]
Phase 2 trial evaluating a vaccine therapy with paclitaxel and carboplatin in patients undergoing surgery for advanced ovarian cancer, prima…
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with carboplatin for relapsed or refractory ovarian, fallopian tube, or p…
-
EMA guidance · 2022-07-22EMA recommends restricting use of cancer medicine Rubraca
EMA recommends restricting the use of the cancer medicine Rubraca (rucaparib) to specific patient groups due to safety or effectiveness cons…
-
CLINICAL_TRIALS trial_result · 2022-06-24Clinical Trial Update: Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update for paclitaxel and ganetespib in recurrent ovarian, fallopian tube, or primary peritoneal cancer; study terminated wit…
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 [Phase 1, Phase 2]
Phase 1/2 trial evaluating NY-ESO-1–targeted T-cell therapy with or without decitabine in patients with NY-ESO-1–expressing advanced cancers…
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas [Phase 2]
Phase 2 trial investigating autologous dendritic cells loaded with autologous tumor-associated antigens for advanced epithelial ovarian carc…
-
FDA approval · 2022-04-13FDA Approved: ALYMSYS — Original Application (Amneal Pharmaceuticals LLC)
FDA approves ALYMSYS as a biosimilar to bevacizumab (bevaczizumab-maly) from Amneal Pharmaceuticals LLC under an original Biologics License …
-
CLINICAL_TRIALS trial_result · 2022-03-15Clinical Trial Update: BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei [Phase 2]
Phase 2 clinical trial update for BromAc in recurrent pseudomyxoma peritonei and peritoneal mucinous tumors; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway [Phase 3]
A Phase 3 trial comparing four quadrants transverse abdominus plane block with plain and liposomal bupivacaine versus thoracic epidermal ana…
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients [Phase 3]
Phase 3 ARIEL4 trial comparing rucaparib to chemotherapy in BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancer has completed …
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery [Phase 2]
Phase 2 trial update on IGFBP-2 vaccine with combination chemotherapy for stage III-IV ovarian, fallopian tube, or primary peritoneal cancer…
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update for an autologous oxidized tumor cell lysate vaccine in recurrent ovarian/fallopian tube/primary peritoneal cancer; tr…
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]
Phase 1 clinical trial update for a vaccine therapy in ovarian epithelial, primary peritoneal, or fallopian tube cancer with completed statu…
-
FDA approval · 2021-09-09FDA Approved: TALZENNA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TALZENNA (talazoparib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2021-09-02Clinical Trial Update: Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 study examining whether physical activity tracked by Fitbit Charge 2 improves quality of life in participants with recurrent ovarian…
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating surufatinib with toripalimab for refractory metastatic digestive system carcinoma and primary peritoneal cancer is …